Press release Cepep III AB

Cepep III AB together with Burnham Institute files a provisional patent application in USA on cell-specific cell-penetrating peptides

March 22, 2006 – Cepep in collaboration with Burnham Institute of Medical Research, CA, USA , files a provisional US patent application on chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and /or diagnostic agents for cancer treatment and/or diagnostic purposes. These constructs result in cancer homing and cell penetration both in vitro and in vivo.

For further information please contact:
Prof. Ülo Langel, Chairman of Board
+46-8-161793, ulo@neurochem.su.se
www.cepep.se

About Cepep II and III AB
Cepep is a pharmaceutical R&D company focusing on the development of novel strategies for drug delivery by using a unique and proprietary technology platform on cell-penetrating peptides. Cepep collaborates with Burnham Institute, USA, Unibioscreen, Belgium and several universities.
Cepep employs 4 people, most of them working on R&D. Cepep owns a patent on cell-penetrating peptides and their applications.